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PURPOSE
The primary aim of














HME: The drug-polymer combinations (Table 1) for compressed core tablet and 3D printed shell tablet were
selected and physical mixtures were blended using V-shell blender (MaxiBlendTM, GlobePharma, North Brunswick,
NJ, USA). The physical blends of different drug ratios of Atorvastatin calcium (ATV) and Kollidon® VA 64,
Amlodipine besylate (AML) with polyvinyl alcohol (PVA) for shell printed tablets were extruded using a
ThermoFischer standard screw configuration on a co-rotating twin-screw extruder (11 mm Process 11™,
ThermoFischer Scientific, Karlsruhe, Germany) with die nozzle size of 1.50 mm diameter to be fit for later use as
feeding filaments for 3D printing. DSC: The pure materials and milled extrudates were characterized by performing
Differential Scanning Calorimetry (TA Instruments). Three-point bend test (Repka-Zhang test):The printability
and mechanical properties of the extruded filaments were evaluated using a texture analyzer (TA-XT2i Texture
Analyzer by Stable Micro Systems, UK). 3D printing of Shell tablet: The printable filaments were printed with
varied infill densities using a Grid and lines pattern on an FDM-3D printer (Prusa i3 3D printer, Prusa Research,
Czech Republic). Dissolution studies: The in vitro drug release studies were conducted in 900 mL pH 6.8, 0.05 M
phosphate buffer for ATV and pH 2.2, 0.01 N HCl for AML and 0.1% polysorbate 80 in phosphate buffer with pH 6.8
for the shell-core combination.
RESULT(S) 
CONCLUSION(S)
Combining HME technology with 3D printing resulted in the effective preparation of ATV-AML shell-core tablets. With the newly constructed
fixed-dose combination tablet and 3D printing design parameters, customized personalized oral dosage forms with the appropriate amount
of drug and modifying the dissolution profile based on patient demands could be manufactured.






F0 913.54±13.24 94.95±1.38 3.67±0.05 63.31± 0.92 Yes
F3 904.17±𝟏𝟑 83.57±9.44 3.45± 0.99 69.65±7.86 Yes
F4 732.53±184.49 68.06±13.94 3.48±0.80 56.77±11.61 Yes
F5 595.04±149.46 64.32±11.40 4.02±0.52 53.60±9.50 Yes
Table 1. Ingredients of HME based filament
Figure 3. Repka-Zhang  (3pb) test for  
extruded filaments mechanical properties
Table 2. Filaments 3-point bend test results. (n=10, mean ± SD) 
Figure 2. (1) Extrudate compressed tablets; 
(2) 3DP tablets with different infill%














Figure 3. In vitro drug release of pure ATV, compressed tablets, 
and milled extruded filaments.
Formulation Ingredients
Drug load (w/w) Polymer (w/w) Excipients (w/w)
Ref. 
standard
F0 0 100%PLA -
Stage 1:
Core-tablet
F1 20%ATV 80%VA64 -
F2 30%ATV 70%VA64 -
Stage 2:
Shell- tablet
F3 5%AML 95%PVA -
F4 2.5%AML 87.5%PVA 10%Sorbitol
F5 2%AML 88%PVA 10%Sorbitol
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